microRNA-214的下调表达对不同种类淋巴瘤细胞耐药性的影响

发布时间：2018-02-11 17:12

本文关键词： 淋巴瘤小分子核糖核酸- 多药耐药性　出处：《中国临床药理学杂志》2017年10期 　论文类型：期刊论文

【摘要】：目的研究microRNA-214对不同种类淋巴瘤细胞耐药性的影响。方法选择几种不同的淋巴瘤细胞,分别命名为Jurkat细胞实验组、OCI-Ly3细胞实验组及Raji细胞实验组,将健康人外周血淋巴细胞(Scr)作为对照组。细胞分别被敲除miR-214并给予不同的药物刺激。用荧光定量PCR法检测不同淋巴瘤细胞内miR-214的表达量;以CCK-8法检测敲除miR-214后的淋巴瘤细胞存活率;以MTT比色法检测敲除miR-214后不同淋巴瘤细胞对不同药物的敏感性;以蛋白质免疫印迹法检测BCL11B蛋白表达水平;用荧光素酶报告技术检测BCL11B是否为miR-214的靶基因。结果 Jurkat、OCI-Ly3及Raji细胞在实验组的miR-214的表达量分别为27.21±1.37,17.13±2.11,19.31±2.46,均明显高于对照组的1.17±0.28,差异有统计学意义(均P0.05)。敲除miR-214后,与对照组的Scr细胞存活率(86±12)%相比,Jurkat、OCI-Ly3及Raji细胞在实验组的细胞存活率分别为(42±13)%,(65±11)%,(58±7)%,差异有统计学意义(均P0.05)。抑制miR-214表达后,对照组Scr细胞对阿霉素、环磷酰胺、柔红霉素、丝裂霉素C和长春新碱的耐药敏感性分别为0.46±0.11,1.96±0.13,1.15±0.22,3.90±0.52,0.52±0.15,Jurkat细胞对5种药物的耐药敏感性分别为0.32±0.07,0.76±0.16,0.73±0.13,2.36±0.16,0.37±0.06,OCI-Ly3细胞对5种药物的耐药敏感性分别为0.28±0.06,0.91±0.12,0.55±0.09,2.01±0.36,0.23±0.07,Raji细胞对5种药物的耐药敏感性分别为0.36±0.04,0.82±0.08,0.64±0.07,3.31±0.21,0.35±0.05,与对照组比较,差异有统计学意义(P0.05)。BCL11B是miR-214的靶基因。结论抑制miR-214表达能够降低不同种类淋巴瘤细胞的存活率,并降低白血病淋巴细胞的多药耐药性,这种作用可能与miR-214抑制其靶基因BCL11B的表达相关。
[Abstract]:Objective to study the effects of microRNA-214 on different types of lymphoma cell resistance. Methods several different lymphoma cells, named Jurkat cells in the experimental group, the experimental group of OCI-Ly3 cells and Raji cells in experimental group, the peripheral blood lymphocytes of healthy adults (Scr) as the control group. Cells were knocked out miR-214 and given different drugs stimulation. Expression by fluorescence quantitative PCR assay in miR-214 lymphoma cells by CCK-8 assay; knockout survival rate after miR-214 lymphoma cells by MTT assay; miR-214 knockdown on the sensitivity of different drugs in different lymphoma cells; the expression level of BCL11B protein was detected by Western blotting with BCL11B detection; luciferase reporter whether technology is the target gene of miR-214. The results of Jurkat, OCI-Ly3 and Raji expression of miR-214 cells in the experimental group were 27.21 + 1.37,17.13 + 2.11,19.31 + 2.46, significantly higher than the control group of 1.17 + 0.28, the difference was statistically significant (P0.05). MiR-214 knockdown, the survival rate of Scr cells and the control group (86 + 12)% compared to Jurkat, OCI-Ly3 cells and Raji cells in the experimental group, the survival rates were 13 (42.)%, (65 + 11)% and (58 + 7)%, the difference was statistically significant (P0.05). After inhibition of miR-214 expression, the control group of Scr cells to adriamycin, cyclophosphamide, daunorubicin and vincristine resistant sensitivity to mitomycin C were 0.46 + 0.11,1.96 + 0.13,1.15 + 0.22,3.90 + 0.52,0.52 + 0.15. Drug sensitivity of Jurkat cells to 5 kinds of drugs were 0.32 + 0.07,0.76 + 0.16,0.73 + 0.13,2.36 + 0.16,0.37 + 0.06, drug sensitivity of OCI-Ly3 cells to 5 kinds of drugs were 0.28 + 0.06,0.91 + 0.12,0.55 + 0.09,2.01 + 0.36,0.23 + 0.07, drug sensitivity of Raji cells to 5 kinds of drugs were 0.36. 0.04,0.82 + 0.08,0.64 + 0.07,3.31 + 0.21,0.35 + 0.05, compared with the control group, the difference was statistically significant (P0.05).BCL11B is the target gene of miR-214. Conclusion the survival rate of inhibition of miR-214 expression can reduce the lymphoma cells of different types, and reduce the multidrug resistance of leukemia cells, the expression of this effect may be related to the inhibition of miR-214 target gene BCL11B related.

【作者单位】：聊城市人民医院药学部;
【基金】：山东省药学会临床药学奥赛康中青年科研基金资助项目(Sdpa-ask-2013-05)
【分类号】：R97

【相似文献】